Taj
Quality Medicines Diseases Newsroom Feed back Contact us
Search

 
 
 

Reports and Key Figures books
Reports and Key Figures
Key Figures 2004
 
Key Figures in millions of CHF
 
Figures reported in the financial statements
 
Continuing businesses a)
 
 
2004
%change
2004
2003
%change
CHF/LC
CHF/LC
Sales
31,273
0/+3
29,522
27,190
+9/+12
Research and Development
5,093
+7/+11
5,053
4,624
+9/+14
EBITDA b)
9,566
+11/+15
9,231
8,038
+15/+19
Operating profit before exceptional items
7,254
+16/+20
6,950
5,793
+20/+24
Operating profit
8,979
+61/+65
6,179
5,520
+12/+16
Financial income
(359)
-46
(339)
(630)
-46
Net income before exceptional items c)
-
-
4,343
3,371
+29
Net Income
6,641
+116
4,339
3,074
+41

a) Continuing businesses includes the Pharmaceuticals and Diagnostics businesses, treasury and other corporate activities. Consumer Health (OTC) and Vitamins and Fine Chemicals are reported as discontinuing businesses.
b) EBITDA: Earnings before exceptional items and before interest and other financial income, tax, depreciation and amortisation, including impairment. This corresponds to operating profit before exceptional items and before depreciation and amortisation, including impairment.
c) Net income before exceptional items and EPS before exceptional items are calculated as shown on page 143 of the Annual Report.


Ratios
 
Figures reported in the financial statements
% change
Continuing businesses a)
 
% change
2004
2004
2003
EPS d) before exceptional items in CHF
-
-
5.07
3.97
+28
EPS d) in CHF
7.81
+116
5.09
3.62
+41
Research and development as % of sales
16.3
17.1
17.0
EBITDA as % of sales
30.6
31.3
29.6
Operating profit before exceptional items as % of sales
23.2
23.5
21.3
Effective tax rate %
24.7
28.4
29.0
Net income as % of sales
21.2
14.7
11.3
d) EPS: Earnings per share and non-voting equity security (diluted).

Liquidity in Millions of CHF
 
Taj Pharmaceuticals Group 31 December 2004
Net liquidity
11,674
Total assests
58,076
Equity and minority interests
33,293
Dept
8,960
Equity ratio e)
57%
Dept-equity ratio f)
27%

e) Equity ratio: Equity and minority interests as a percentage of total assets.
f) Debt-equity ratio: Debt as a percentage of equity (including minority interests).


Sales by Division in millions of CHF
2004
%change (CHF)
%change (LC)
Pharmaceuticals
21,695
+10
+13
Diagnostics
7,827
+6
+8
Sales continung business
29,522
+9
+12
Consumer Health (OTC)
1,751
Vitamins and Fine Chemicals
-
Total
31,273



Sales by Region (all businesses) in millions of CHF
 
2004
share in % (2004)
Switzerland
442
European Union
10,563
Rest of Europe
993
Europe
11,998
38.5
North America
11,025
33.5
Latin America
1,825
6
Japan
3,875
Rest of Asia
1,553
Asia
5,428
17
Africa Australia Oceania
997
3
Total
31,273



Employees by Division
 
2004
Change
Share in % (2004)
Pharmaceuticals
45,108
+573
70
Diagnostics
19,109
+807
29
Others
377
-53
1
TAJ Group
64,594
+1,327
100



Employees by Region
 
2004
Change
Share in % (2004)
Europe (all)
28,601
+320
44
Switzerland alone
7,498
+309
North America
19,715
+1,290
31
Latin America
4,971
-91
8
Asia (all)
9,885
-167
15
Japan alone
5,663
-340
Africa Australia Oceania
1,422
-25
2
Taj Group
64,594
+1,327

 
  Company   Products   Diseases   Health   Media   R & D   Sustainability  
  Figure & Reports   Investors   Countries   E-mail us      Divisions   Contact us   Home  

         Copyright 2005 TAJ Pharmaceuticals Limited ,434 LAXMI PLAZA (LAXMI INDUSTRIAL ESTATE) NEW LINK ROAD Andheri (W) MUMBAI-53. INDIA

Site Requirements : Internet Explorer 5.0+ or Netscape 5.0+, Flash Player 5.0 & Real Player 8 Basic
To get in touch with us, call on 91-22-2637 4592, 91--22-2637 4593 or fax us at 91-22-2634 1274 

| Privacy Policy | Terms & Conditions | Sitemap |